Rich Pharmaceuticals (RCHA) 0.0013 $RCHA
Rich Pharmaceuticals Retains Contract Research Organization, CMIC, to Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in Thailand
PR Newswire - Mon Apr 04, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company"
, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that is has retained the services of an Asian Contract Research Organization ("CRO" , CMIC ASIA-PACIFIC, PTE. LTD. ("CMIC" , to run Rich's upcoming Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. CMIC is considered to be one of Asia's top CRO's for running clinical oncology studies.
Rich Pharmaceuticals Further Extends CRO Agreement with Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in the United States
PR Newswire - Wed Mar 30, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company" , a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that it has extended its agreement with Theradex Systems, Inc. ("Theradex" , a leading global Contract Research Organization ("CRO" , to manage the Company's clinical sites in the United States. Through this continued partnership, Theradex will lead the Company in commencing its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients in the United States.
Rich Pharmaceuticals, Inc. Announces Reverse Split
PR Newswire - Wed Feb 10, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the "Company" today announced a 1-for-100 reverse split of its issued and outstanding shares of common stock effective at the opening of trading on Thursday, February 11, 2016. The Company's common stock will trade on a split-adjusted basis under new CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After 20 trading days, the common stock will commence trading under the ticker symbol (RCHA).
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 159.19 (-0.68), ATRA: 18.17 (-0.96), STML: 8.93 (-0.23), SNTA: 0.37 (+0.01), ATNM: 1.81 (-0.09), SNDX: 13.20 (-0.51), BLCM: 13.02 (-0.33), BPTH: 2.50 (unch), TEVA: 53.79 (-0.86), AGIO: 56.80 (-4.19), XLRN: 36.19 (-1.04), ARRY: 3.79 (-0.06)
Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS
PR Newswire - Mon Dec 28, 6:00AM CST
Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the "Company" is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration (FDA) to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. The FDA has approved the Company's Investigational New Drug (IND) application and has approved the Company's commencement of a clinical program titled "A Phase 1/2, Evaluation of the Safety and Efficacy of RP-323 in Combination with all-trans-Retinoic Acid, Sodium Butyrate, and 1a, 25-dihydroxyvitamin D3 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)". This approval gives the Company an immediate go ahead to start patient enrollment for a Phase 1/2 study using Rich Pharmaceuticals' lead compound RP-323 in clinical trials.
Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)
PR Newswire - Mon Nov 23, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" , with the advice and guidance of Theradex Systems, Inc., Rich's Contract Research Organization, has submitted additional information to the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) to conduct clinical trials for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS). This is the third submission (#0003) to the FDA by Rich to continue the efforts to move forward with the next phase of clinical studies using RP-323 to treat AML and MDS patients.
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
PR Newswire - Tue Aug 11, 10:33AM CDT
Rich Pharmaceuticals, Inc. (OTCQB: RCHAE) ("Rich Pharmaceuticals" or the "Company" announced today that Dr. Richard A. Salvador will be joining the corporate board. Dr. Salvador brings over 40 years of biotechnology experience to Rich Pharmaceuticals.
Rich Pharmaceuticals, Inc. Announces Letter of Intent with Faculty of Medicine at Khon Kaen University to Conduct Acute Myelocytic Leukemia Clinical Trials
PR Newswire - Tue Mar 24, 7:35AM CDT
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich Pharmaceuticals" or the "Company" , a clinical-stage biotechnology company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML) and Hodgkin's Lymphoma, announced that it has entered into a Letter of Intent with The Faculty of Medicine at Khon Kaen University, Thailand to conduct clinical trials using Rich's lead molecule, RP-323 in treating AML patients.
Biotechnology And The Road To Innovation: What Companies Are Pushing New Innovation In Today's Market?
ACCESSWIRE - Thu Mar 19, 8:15AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 19, 2015 / Globally, the market for biotechnology has been growing at a rate of over 10% annually according to a report from IBISWorld. Annual revenue is on the cusp of breaking $290 Billion and has many sub sectors contributing to its further expansion. Industry firms have thrived as technological advances have facilitated new discoveries and ignited higher demand from firms in the pharmaceuticals and agricultural sectors. According to the report, industry growth is forecast to continue "skyrocketing in the next five-year period" where investment in biotechnology from around the world increases, particularly from emerging economies.
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
PR Newswire - Wed Feb 04, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich" or the "Company" , a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.
WSA Speaks to Three Companies on the Rise
Marketwired - Tue Dec 02, 10:27AM CST
ClearOne (NASDAQ: CLRO) CEO Zee Hakimoglu discussed the company's favorable Q3 results reporting 27% revenue growth from last year with solid profitability. She outlined ClearOne's products and patents and talked about two recent acquisitions and how these acquisitions have positioned ClearOne favorably in their traditional audio conferencing market as well as in the emerging media collaboration market.
CLRO: 11.09 (+0.06)
Rich Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to FDA for the Treatment of Acute Myelocytic Leukemia and Myelodysplastic Syndrome
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" , a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow.
Rich Pharmaceuticals Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights for Indication, Patents and Intellectual Property Related to the Treatment of Hodgkin's Lymphoma
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" Rich, a cancer therapeutics development company announced that it has entered into an agreement with Richard L. Chang Holdings, LLC based in New Jersey for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin's Lymphoma. Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin Lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Currently, this disease affects over 100,000 patients annually. In 2014, it is estimated that there will be 9,190 new cases of Hodgkin lymphoma and an estimated 1,180 people will die of this disease.
Rich Pharmaceuticals Announces Up to $4.5 Million Finance Deal to Fund Phase 2 Clinical Trials in Acute Myelocytic Leukemia
GlobeNewswire - Thu Oct 09, 6:00AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company" Rich, a cancer therapeutics development company announced that it has entered into an investment agreement up to $4.5 Million with Macallan Partners, LLC headquartered in White Plains, NY. The investment commences under the Macallan Partners, LLC Agreement filed under Form S-1 and recently was declared effective by the Securities and Exchange Commission.
Rich Pharmaceuticals Retains Contract Research Organization, CMIC, to Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in Thailand
PR Newswire - Mon Apr 04, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company"
, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that is has retained the services of an Asian Contract Research Organization ("CRO" , CMIC ASIA-PACIFIC, PTE. LTD. ("CMIC" , to run Rich's upcoming Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. CMIC is considered to be one of Asia's top CRO's for running clinical oncology studies. Rich Pharmaceuticals Further Extends CRO Agreement with Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in the United States
PR Newswire - Wed Mar 30, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich" or the "Company"
, a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today that it has extended its agreement with Theradex Systems, Inc. ("Theradex" , a leading global Contract Research Organization ("CRO" , to manage the Company's clinical sites in the United States. Through this continued partnership, Theradex will lead the Company in commencing its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients in the United States. Rich Pharmaceuticals, Inc. Announces Reverse Split
PR Newswire - Wed Feb 10, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the "Company"
today announced a 1-for-100 reverse split of its issued and outstanding shares of common stock effective at the opening of trading on Thursday, February 11, 2016. The Company's common stock will trade on a split-adjusted basis under new CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After 20 trading days, the common stock will commence trading under the ticker symbol (RCHA). Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 159.19 (-0.68), ATRA: 18.17 (-0.96), STML: 8.93 (-0.23), SNTA: 0.37 (+0.01), ATNM: 1.81 (-0.09), SNDX: 13.20 (-0.51), BLCM: 13.02 (-0.33), BPTH: 2.50 (unch), TEVA: 53.79 (-0.86), AGIO: 56.80 (-4.19), XLRN: 36.19 (-1.04), ARRY: 3.79 (-0.06)
Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS
PR Newswire - Mon Dec 28, 6:00AM CST
Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the "Company"
is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration (FDA) to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. The FDA has approved the Company's Investigational New Drug (IND) application and has approved the Company's commencement of a clinical program titled "A Phase 1/2, Evaluation of the Safety and Efficacy of RP-323 in Combination with all-trans-Retinoic Acid, Sodium Butyrate, and 1a, 25-dihydroxyvitamin D3 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)". This approval gives the Company an immediate go ahead to start patient enrollment for a Phase 1/2 study using Rich Pharmaceuticals' lead compound RP-323 in clinical trials. Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)
PR Newswire - Mon Nov 23, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"
, with the advice and guidance of Theradex Systems, Inc., Rich's Contract Research Organization, has submitted additional information to the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) to conduct clinical trials for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS). This is the third submission (#0003) to the FDA by Rich to continue the efforts to move forward with the next phase of clinical studies using RP-323 to treat AML and MDS patients. Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
PR Newswire - Tue Aug 11, 10:33AM CDT
Rich Pharmaceuticals, Inc. (OTCQB: RCHAE) ("Rich Pharmaceuticals" or the "Company"
announced today that Dr. Richard A. Salvador will be joining the corporate board. Dr. Salvador brings over 40 years of biotechnology experience to Rich Pharmaceuticals. Rich Pharmaceuticals, Inc. Announces Letter of Intent with Faculty of Medicine at Khon Kaen University to Conduct Acute Myelocytic Leukemia Clinical Trials
PR Newswire - Tue Mar 24, 7:35AM CDT
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich Pharmaceuticals" or the "Company"
, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML) and Hodgkin's Lymphoma, announced that it has entered into a Letter of Intent with The Faculty of Medicine at Khon Kaen University, Thailand to conduct clinical trials using Rich's lead molecule, RP-323 in treating AML patients. Biotechnology And The Road To Innovation: What Companies Are Pushing New Innovation In Today's Market?
ACCESSWIRE - Thu Mar 19, 8:15AM CDT
CORAL GABLES, FL / ACCESSWIRE / March 19, 2015 / Globally, the market for biotechnology has been growing at a rate of over 10% annually according to a report from IBISWorld. Annual revenue is on the cusp of breaking $290 Billion and has many sub sectors contributing to its further expansion. Industry firms have thrived as technological advances have facilitated new discoveries and ignited higher demand from firms in the pharmaceuticals and agricultural sectors. According to the report, industry growth is forecast to continue "skyrocketing in the next five-year period" where investment in biotechnology from around the world increases, particularly from emerging economies.
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
PR Newswire - Wed Feb 04, 8:45AM CST
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich" or the "Company"
, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials. WSA Speaks to Three Companies on the Rise
Marketwired - Tue Dec 02, 10:27AM CST
ClearOne (NASDAQ: CLRO) CEO Zee Hakimoglu discussed the company's favorable Q3 results reporting 27% revenue growth from last year with solid profitability. She outlined ClearOne's products and patents and talked about two recent acquisitions and how these acquisitions have positioned ClearOne favorably in their traditional audio conferencing market as well as in the emerging media collaboration market.
CLRO: 11.09 (+0.06)
Rich Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to FDA for the Treatment of Acute Myelocytic Leukemia and Myelodysplastic Syndrome
GlobeNewswire - Thu Oct 23, 6:09AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has submitted an investigational new drug (IND) application to conduct a Phase 2 clinical trial for its lead compound RP-323 in Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) with the U.S. Food and Drug Administration (FDA). Rich plans to initiate a multicenter, Phase 2 clinical study using RP-323 to treat AML and MDS patients. According to the American Cancer Society surveillance research group in 2014, it is estimated there will be 18,860 new cases of AML and 10,460 deaths from acute myeloid leukemia (AML) in the United States. Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells and there are abnormal (blast) cells in the blood and/or bone marrow. Rich Pharmaceuticals Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights for Indication, Patents and Intellectual Property Related to the Treatment of Hodgkin's Lymphoma
GlobeNewswire - Mon Oct 13, 8:45AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
Rich, a cancer therapeutics development company announced that it has entered into an agreement with Richard L. Chang Holdings, LLC based in New Jersey for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin's Lymphoma. Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin Lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Currently, this disease affects over 100,000 patients annually. In 2014, it is estimated that there will be 9,190 new cases of Hodgkin lymphoma and an estimated 1,180 people will die of this disease. Rich Pharmaceuticals Announces Up to $4.5 Million Finance Deal to Fund Phase 2 Clinical Trials in Acute Myelocytic Leukemia
GlobeNewswire - Thu Oct 09, 6:00AM CDT
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company"
Rich, a cancer therapeutics development company announced that it has entered into an investment agreement up to $4.5 Million with Macallan Partners, LLC headquartered in White Plains, NY. The investment commences under the Macallan Partners, LLC Agreement filed under Form S-1 and recently was declared effective by the Securities and Exchange Commission. 
